Israel - englanti - Ministry of Health

alexion pharma israel ltd - andexanet alfa - powder for solution for infusion - andexanet alfa 200 mg/vial - andexanet alfa - for adult patients treated with a direct factor xa (fxa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

Israel - englanti - Ministry of Health

alexion pharma israel ltd - ravulizumab - concentrate for solution for infusion - ravulizumab 100 mg/ml - ravulizumab - ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (pnh): * in patients with haemolysis with clinical symptom(s) indicative of high disease activity. * in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome ahus who are complement inhibitor treatment naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab. ultomiris is indicated in the treatment of adult patients with generalized myasthenia gravis (gmg) who are antiacetylcholine receptor (achr) antibody-positive.

Kanada - englanti - Health Canada

alexion pharma gmbh - selumetinib (selumetinib sulfate) - capsule - 10mg - selumetinib (selumetinib sulfate) 10mg

Kanada - englanti - Health Canada

alexion pharma gmbh - selumetinib (selumetinib sulfate) - capsule - 25mg - selumetinib (selumetinib sulfate) 25mg

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - eculizumab 300mg;  ;  ;   - solution for infusion - 300mg/30ml - active: eculizumab 300mg       excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection - soliris® is indicated for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh)to reduce haemolysis.

Euroopan unioni - englanti - EMA (European Medicines Agency)

alexion europe sas - sebelipase alfa - lipid metabolism, inborn errors - other alimentary tract and metabolism products, - kanuma is indicated for long-term enzyme replacement therapy (ert) in patients of all ages with lysosomal acid lipase (lal) deficiency.

Euroopan unioni - englanti - EMA (European Medicines Agency)

alexion europe sas - asfotase alfa - hypophosphatasia - other alimentary tract and metabolism products, - strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.

Euroopan unioni - englanti - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinuria, paroxysmal - immunosuppressants - soliris is indicated in adults and children for the treatment of:paroxysmal nocturnal haemoglobinuria (pnh).evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). atypical haemolytic uremic syndrome (ahus).soliris is indicated in adults for the treatment of:refractory generalized myasthenia gravis (gmg) in patients who are anti-acetylcholine receptor (achr) antibody-positive (see section 5.1).neuromyelitis optica spectrum disorder (nmosd) in patients who are anti-aquaporin-4 (aqp4) antibody-positive with a relapsing course of the disease.

Kanada - englanti - Health Canada

alexion pharma gmbh - asfotase alfa - solution - 40mg - asfotase alfa 40mg - enzymes

Kanada - englanti - Health Canada

alexion pharma gmbh - asfotase alfa - solution - 40mg - asfotase alfa 40mg - enzymes